AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35450055 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (3 mg/kg/day for 5 days)
Number of subjects: 72
Study 35450055 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline infusion (50 ml/day for 5 days)
Number of subjects: 72
Study 35450055 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion
Number of subjects: 72
Study 35450055 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline infusion
Number of subjects: 72
Study 32748404 — intervention group
Group type: EXPERIMENTAL
Intervention: Video invitation on a USB
Number of subjects: 1176
Study 32748404 — intervention group
Group type: COMPARATOR
Intervention: Control group (invitation letter only)
Number of subjects: 1176
Study 32748404 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who watched the video invitation
Number of subjects: 1176
Study 32748404 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with lower income
Number of subjects: 1176
Study 34049902 — intervention group
Group type: EXPERIMENTAL
Intervention: eTRIO (online caregiver communication education modules for oncology clinicians)
Number of subjects: 270
Study 34049902 — intervention group
Group type: COMPARATOR
Intervention: Control (Australian State Government Health website on caregivers)
Number of subjects: 270
Study 32085793 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive mesenteric excision (EME)
Number of subjects: 116
Study 32085793 — intervention group
Group type: COMPARATOR
Intervention: Conventional ileocolic resection with limited mesenteric excision (LME)
Number of subjects: 116
Study 33558198 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Pain Assessment Protocol (SPAP)
Number of subjects: 101
Study 33558198 — intervention group
Group type: COMPARATOR
Intervention: Routine care (comparison group)
Number of subjects: 101
Study 32149929 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive chevron osteotomy
Number of subjects: 39
Study 32149929 — intervention group
Group type: COMPARATOR
Intervention: Open distal chevron osteotomy
Number of subjects: 39
Study 35294297 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking meditation (WM) group
Number of subjects: 33
Study 35294297 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 33
Study 32536425 — intervention group
Group type: EXPERIMENTAL
Intervention: TPVB with 20 mL 0.25% bupivacaine
Number of subjects: 40
Study 32536425 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TPVB)
Number of subjects: 40
Study 32536425 — intervention group
Group type: EXPERIMENTAL
Intervention: TPVB
Number of subjects: 40
Study 32505932 — intervention group
Group type: EXPERIMENTAL
Intervention: Case group (infants with hyperbilirubinemia)
Number of subjects: 100
Study 32505932 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy infants)
Number of subjects: 100
Study 36342252 — intervention group
Group type: EXPERIMENTAL
Intervention: 532-nm picosecond laser treatment (3 monthly treatments, 800 ps pulse duration, 4-6mm spot size, 0.1 to 0.6J/cm2 fluence)
Number of subjects: 25
Study 36342252 — intervention group
Group type: EXPERIMENTAL
Intervention: 532-nm picosecond laser treatment
Number of subjects: 25
Study 33756525 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality multi-ingredient nutritional supplement (SUPP) - 20 g whey protein, 2 g leucine, 2.5 g creatine monohydrate, 300 mg calcium citrate, 1000 IU vitamin D, ingested twice daily
Number of subjects: 26
Study 33756525 — intervention group
Group type: COMPARATOR
Intervention: Isontrogenous isoenergetic placebo (PL) - 20 g collagen peptides, 1.4 g alanine, 0.6 g glycine, ingested twice daily
Number of subjects: 26
Study 33756525 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality multi-ingredient nutritional supplement (SUPP)
Number of subjects: 26
Study 33756525 — intervention group
Group type: COMPARATOR
Intervention: Isontrogenous isoenergetic placebo (PL)
Number of subjects: 26
Study 32247794 — intervention group
Group type: EXPERIMENTAL
Intervention: Subperiosteal drain (SPD)
Number of subjects: 133
Study 32247794 — intervention group
Group type: COMPARATOR
Intervention: Subdural drain (SDD)
Number of subjects: 133
Study 34611051 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin 6 mg/day for 4 weeks
Number of subjects: 14
Study 34611051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 33819166 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy with bilevel positive airway pressure (BiPAP) ventilation
Number of subjects: 60
Study 33819166 — intervention group
Group type: COMPARATOR
Intervention: Osteopathic manipulative respiratory and physical therapy techniques
Number of subjects: 60
Study 32949031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam (C/T) 3-g dose (2 g ceftolozane and 1 g tazobactam) administered via a 1-hour infusion every 8 hours
Number of subjects: 0
Study 32949031 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 0
Study 32244908 — intervention group
Group type: EXPERIMENTAL
Intervention: Cake and cookies intake
Number of subjects: 136
Study 32244908 — intervention group
Group type: EXPERIMENTAL
Intervention: Legumes intake
Number of subjects: 136
Study 32244908 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat dairy and cheese intake
Number of subjects: 136
Study 32244908 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet quality scores (derived Mediterranean and DASH diet)
Number of subjects: 136
Study 33653009 — intervention group
Group type: EXPERIMENTAL
Intervention: High-NO3- (HN: 2 × 70 mL BJ/day)
Number of subjects: 62
Study 33653009 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-NO3- (MN: 70 mL BJ/day)
Number of subjects: 62
Study 33653009 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-NO3- (LN: 70 mL BJ on alternate days)
Number of subjects: 62
Study 33653009 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL: 70 mL of NO3--depleted BJ on alternate days)
Number of subjects: 62
Study 32868354 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) VL testing (Cepheid Xpert HIV-1 Viral Load system) with same-day result and immediate ART adherence counselling
Number of subjects: 150
Study 32868354 — intervention group
Group type: COMPARATOR
Intervention: Standard laboratory-based VL testing (Abbott m2000sp/m2000rt) with results available 1 month later and ART adherence counselling at that time
Number of subjects: 150
Study 35907163 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor daylight photodynamic therapy (idl‐PDT)
Number of subjects: 16
Study 35907163 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional photodynamic therapy (c‐PDT)
Number of subjects: 16
Study 32229771 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training with protein supplement (21 g whey protein per day, 90 kcal)
Number of subjects: 70
Study 32229771 — intervention group
Group type: COMPARATOR
Intervention: Resistance training with placebo (sucrose, 90 kcal)
Number of subjects: 70
Study 32229771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RT + S and RT + P)
Number of subjects: 70
Study 34560137 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous belimumab 10 mg/kg
Number of subjects: 448
Study 34560137 — intervention group
Group type: COMPARATOR
Intervention: Placebo with standard therapy (cyclophosphamide/azathioprine or mycophenolate mofetil)
Number of subjects: 448
Study 32127350 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support intervention
Number of subjects: 264
Study 32127350 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 264
Study 34069621 — intervention group
Group type: EXPERIMENTAL
Intervention: Group multicomponent cognitive‐behavioral therapy
Number of subjects: 120
Study 34069621 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 120
Study 32624405 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT + BT
Number of subjects: 1650
Study 32624405 — intervention group
Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 1650
Study 33316385 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (OM3FA)
Number of subjects: 0
Study 33316385 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (as a placebo)
Number of subjects: 0
Study 35938349 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-1 (Trios 3/3Shape)
Number of subjects: 20
Study 35938349 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-2 (Virtuo Vivo/Straumann)
Number of subjects: 20
Study 35938349 — intervention group
Group type: COMPARATOR
Intervention: Control (Impregum/3M Espe)
Number of subjects: 20
Study 35938349 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of digital workflows
Number of subjects: 20
Study 33983051 — intervention group
Group type: EXPERIMENTAL
Intervention: Zelesse cream (monotherapy for non-infectious VV)
Number of subjects: 58
Study 33983051 — intervention group
Group type: EXPERIMENTAL
Intervention: Zelesse cream (adjuvant to antimicrobial therapy for infectious VV)
Number of subjects: 58
Study 32629640 — intervention group
Group type: EXPERIMENTAL
Intervention: All-inside technique
Number of subjects: 70
Study 32629640 — intervention group
Group type: COMPARATOR
Intervention: Inside-out technique
Number of subjects: 70
Study 35353749 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC‐PT (Managing Cancer Care: A Personal Guide)
Number of subjects: 71
Study 35353749 — intervention group
Group type: COMPARATOR
Intervention: Symptom management education (control)
Number of subjects: 71
Study 33439606 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 impact on clinical responsibilities
Number of subjects: 561
Study 33439606 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 impact on professional working time
Number of subjects: 561
Study 33439606 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender impact on job change due to COVID-19
Number of subjects: 561
Study 33439606 — intervention group
Group type: EXPERIMENTAL
Intervention: Home responsibilities impact on job change
Number of subjects: 561
Study 33439606 — intervention group
Group type: EXPERIMENTAL
Intervention: Early retirement plans due to COVID-19
Number of subjects: 561
Study 33439606 — intervention group
Group type: EXPERIMENTAL
Intervention: Later retirement plans due to COVID-19
Number of subjects: 561
Study 33439606 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnout likelihood among women
Number of subjects: 561
Study 33439606 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnout likelihood among non-whites
Number of subjects: 561
Study 33439606 — intervention group
Group type: EXPERIMENTAL
Intervention: Social isolation feelings
Number of subjects: 561
Study 33439606 — intervention group
Group type: EXPERIMENTAL
Intervention: Job satisfaction association with retirement planning
Number of subjects: 561
Study 32643385 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual social communication intervention
Number of subjects: 0
Study 32643385 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer intervention (adapted from the individual intervention)
Number of subjects: 0
Study 32643385 — intervention group
Group type: COMPARATOR
Intervention: Control group (individual intervention without peer involvement)
Number of subjects: 0
Study 35784687 — intervention group
Group type: EXPERIMENTAL
Intervention: Withania somnifera (WS) root capsules, given twice a day for 12 weeks
Number of subjects: 150
Study 35784687 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch capsules), given twice a day for 12 weeks
Number of subjects: 150
Study 32777986 — intervention group
Group type: EXPERIMENTAL
Intervention: 20m shuttle run test with music
Number of subjects: 386
Study 33031171 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 4 weeks, performed on a cycle ergometer with 7.5% bodyweight resistance, consisting of 3×30-s maximal sprints with 2-min active recovery
Number of subjects: 41
Study 33031171 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 4 weeks
Number of subjects: 41
Study 33031171 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 41
Study 36356616 — intervention group
Group type: COMPARATOR
Intervention: Regular wall‐slide exercises
Number of subjects: 20
Study 36356616 — intervention group
Group type: EXPERIMENTAL
Intervention: Theraband at the elbow
Number of subjects: 20
Study 36356616 — intervention group
Group type: EXPERIMENTAL
Intervention: Theraband at the wrist
Number of subjects: 20
Study 32076716 — intervention group
Group type: EXPERIMENTAL
Intervention: Brincidofovir
Number of subjects: 153
Study 32076716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 35126900 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN) support combined with chemotherapy
Number of subjects: 80
Study 35126900 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 80
Study 33031833 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg once daily for 21 days)
Number of subjects: 74
Study 33031833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 33031833 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 74
Study 34413152 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling pleural catheters (IPC)
Number of subjects: 68
Study 34413152 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic thoracentesis (TT)
Number of subjects: 68
Study 34046892 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Epigallocatechin-3-gallate (EGCG)
Number of subjects: 0
Study 34046892 — intervention group
Group type: COMPARATOR
Intervention: Pimecrolimus
Number of subjects: 0
Study 35445839 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of CBD
Number of subjects: 24
Study 35445839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 34590804 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck and trunk stabilization exercises in addition to NDT-B approach
Number of subjects: 40
Study 34590804 — intervention group
Group type: COMPARATOR
Intervention: NDT-B approach (Control)
Number of subjects: 40
Study 36265571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact cord resuscitation (ICR)
Number of subjects: 0
Study 36265571 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping-resuscitation (ECR)
Number of subjects: 0
Study 34523740 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol treatment (800 ?g single dose)
Number of subjects: 189
Study 34523740 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 189
Study 34470722 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab-pemetrexed maintenance plus SBRT
Number of subjects: 0
Study 34470722 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab-pemetrexed alone
Number of subjects: 0
Study 32349927 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) plus docetaxel and estramustine (DE)
Number of subjects: 78
Study 32349927 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 78
Study 35635482 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Ingredient Supplement (MIS)
Number of subjects: 56
Study 35635482 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 56
Study 33880554 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized nutritious food (SNF) treatment (1 of 4 types: 3 fortified-blended foods or a lipid-based nutrient supplement)
Number of subjects: 312
Study 32937598 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based exercise intervention (2 × 45 min/week)
Number of subjects: 105
Study 32937598 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular school physical education class only, 3 × 45 min/week)
Number of subjects: 105
Study 32937598 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based exercise intervention
Number of subjects: 105
Study 32937598 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 35584475 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair basketball (2 hours, twice a week for 12 months)
Number of subjects: 48
Study 35584475 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 48
Study 34228837 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan treatment in the DIRECT-Protect trials
Number of subjects: 1575
Study 35930754 — intervention group
Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI)
Number of subjects: 865
Study 35930754 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI)
Number of subjects: 865
Study 34048061 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (660 nm 200 mW CW applied at a distance of 1 cm to 4 points on the occlusal area, and 810 nm 200 mW CW applied at tissue surface at three points on the buccal and three points on the lingual gingiva for 15 seconds)
Number of subjects: 0
Study 34048061 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study 33491400 — intervention group
Group type: EXPERIMENTAL
Intervention: HVGIC Equia Fil (ART method)
Number of subjects: 131
Study 33491400 — intervention group
Group type: COMPARATOR
Intervention: Filtek Z250 (Conventional method)
Number of subjects: 131
Study 36402375 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue in sodium dodecyl sulfate
Number of subjects: 36
Study 36402375 — intervention group
Group type: COMPARATOR
Intervention: Methylene blue in water
Number of subjects: 36
Study 33514571 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine-rich protein supplement
Number of subjects: 150
Study 33514571 — intervention group
Group type: COMPARATOR
Intervention: Placebo with no supplemented protein
Number of subjects: 150
Study 34486739 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor performance
Number of subjects: 370
Study 34486739 — intervention group
Group type: COMPARATOR
Intervention: Individual and environmental constraints and delayed learning of ADL
Number of subjects: 370
Study 34198122 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted manual-assisted problem-solving training (C-MAP) plus treatment as usual (TAU)
Number of subjects: 221
Study 34198122 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 221
Study 34198122 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted manual-assisted problem-solving training (C-MAP)
Number of subjects: 221
Study 32977969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioplegia with diazoxide (500 μmol/L)
Number of subjects: 12
Study 32977969 — intervention group
Group type: COMPARATOR
Intervention: Cardioplegia alone
Number of subjects: 12
Study 34107724 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsychosocial holistic care models
Number of subjects: 140
Study 34107724 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study 32073660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 50 mg
Number of subjects: 559
Study 32073660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 100 mg
Number of subjects: 559
Study 32073660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 25 mg
Number of subjects: 559
Study 32073660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 50 mg (pooled)
Number of subjects: 559
Study 35569466 — intervention group
Group type: COMPARATOR
Intervention: PBRT alone (64.8–70.2 Gy at 1.8 Gy per fraction daily)
Number of subjects: 1716
Study 35569466 — intervention group
Group type: EXPERIMENTAL
Intervention: PBRT plus short-term ADT
Number of subjects: 1716
Study 35569466 — intervention group
Group type: EXPERIMENTAL
Intervention: PLNRT (45 Gy at 1.8 Gy per fraction, followed by a volume reduction for remaining 19.8–25.2 Gy) plus PBRT plus short-term ADT
Number of subjects: 1716
Study 35569466 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (PLNRT plus PBRT plus short-term ADT)
Number of subjects: 1716
Study 35569466 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (PBRT plus short-term ADT)
Number of subjects: 1716
Study 35569466 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (PBRT alone)
Number of subjects: 1716
Study 34173988 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM.G)
Number of subjects: 70
Study 34173988 — intervention group
Group type: COMPARATOR
Intervention: Control group (C.G)
Number of subjects: 70
Study 32087775 — intervention group
Group type: EXPERIMENTAL
Intervention: Norovirus
Number of subjects: 2298
Study 32087775 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus
Number of subjects: 2298
Study 36240838 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening dosing of antihypertensive medication
Number of subjects: 21104
Study 36240838 — intervention group
Group type: COMPARATOR
Intervention: Morning dosing of antihypertensive medication
Number of subjects: 21104
Study 34078632 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic version of the Integrated Palliative care Outcome Scale (eIPOS)
Number of subjects: 0
Study 34078632 — intervention group
Group type: EXPERIMENTAL
Intervention: eIPOS
Number of subjects: 0
Study 34078632 — intervention group
Group type: COMPARATOR
Intervention: IPOS
Number of subjects: 0
Study 35701067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two times per day)
Number of subjects: 180
Study 35701067 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil (one time per day) and placebo (one time per day)
Number of subjects: 180
Study 35701067 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil (two times per day)
Number of subjects: 180
Study 32077402 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Long Roux Limb Roux-en-Y Gastric Bypass (VLRL-RYGB)
Number of subjects: 444
Study 32077402 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 444
Study 34636057 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glycopyrronium tosylate 3.75%
Number of subjects: 497
Study 34636057 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glycopyrronium tosylate 2.5%
Number of subjects: 497
Study 34636057 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 497